Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losmapimod in moderate COVID-19
NCT04511819Phase 3Terminated
- Sponsor
- Fulcrum Therapeutics
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of losmapimod in coronavirus disease 2019 (COVID-19), sponsored by Fulcrum Therapeutics. Started Aug 2020; status: terminated.
02
Drugs
losmapimod
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04511819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511819.